Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care
- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform
- Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control
ABBOTT PARK, Ill. and
Controlled through an app on a user's personal smartphone device – a unique feature that will be offered with the Omnipod Horizon System – the integrated platform will consist of the trusted tubeless insulin delivery Pod and Abbott's next-generation FreeStyle Libre sensor. Through a simple, intuitive design, glucose data from the sensor will be sent directly to the Pod that is embedded with an algorithm to automatically adjust insulin delivery – without the need for an additional device, connection or tubing. This integrated system will be designed to always remain in automated insulin delivery mode and can be controlled through an app on a user's personal smartphone to manually take a dose of fast-acting insulin, or bolus, before meals for optimal performance. Additionally, the integrated platform is expected to be the first combined system with a fully disposable wearable sensor and pump.
"Abbott is focused on creating future-forward health technologies that simplify how people living with diabetes manage their condition so they can live their best lives," said
"We are excited to expand our partnership with Abbott by building on our consumer-centric Omnipod Horizon platform, which offers unparalleled simplicity, accuracy, and now sensor choice for consumers," said
This connected care solution will integrate both the Omnipod Horizon System and FreeStyle Libre sensor data, offering a seamless option that will fit easily into the lives of people with diabetes. With both
ABBOTT'S AND INSULET'S NEXT-GENERATION TECHNOLOGIES
The FreeStyle Libre 2 system, Abbott's next-generation continuous glucose monitoring (CGM) technology, is currently approved in
Expanding upon the current Omnipod DASH Insulin Management System,
About the Omnipod DASH System:
*The Pod has a waterproof IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof.
**Additional insulins that are indicated for use with the Pod include: Novolog®, Humalog®, Admelog®, Apidra® and FIASP®.
About the FreeStyle Libre System:
Abbott's FreeStyle Libre technology, the #1 sensor-based glucose monitoring system used worldwide,1 reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days, eliminating the need for fingersticks.3 The FreeStyle Libre portfolio has changed the lives of more than two million people across 46 countries5 and has secured partial or full reimbursement in 36 countries, including
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.
1 Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.
2 FreeStyle Libre 2 system is under
3 A fingerstick test using a glucometer is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels; or if hypoglycemia or impending hypoglycemia is reported by the system; or when symptoms do not match the system readings.
5 Data on file, Abbott Diabetes Care.
View original content to download multimedia:http://www.prnewswire.com/news-releases/abbott-and-insulet-partner-to-integrate-next-generation-glucose-sensing-and-automated-insulin-delivery-technologies-for-seamless-diabetes-care-301007119.html
Insulet Investor Contact: Deborah R. Gordon, Vice President, Investor Relations, (978) 600-7717, firstname.lastname@example.org, Insulet Media Contact: Angela Wiczek, Director, Corporate Communications, (978) 932-0611, email@example.com, Abbott Media Contacts: Molly Cornbleet, (847) 420-9540, firstname.lastname@example.org, Rachael Jarnagin, (510) 749-1762, email@example.com or Abbott Investor Contact: Mike Comilla, (224) 668-1872, firstname.lastname@example.org